{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T20:43:45Z","timestamp":1788468225250,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T00:00:00Z","timestamp":1461888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jphs.2016.04.023","type":"journal-article","created":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T20:10:54Z","timestamp":1462306254000},"page":"155-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Protective effects of cilostazol against hemorrhagic stroke: Current and future perspectives"],"prefix":"10.1016","volume":"131","author":[{"given":"Toshinori","family":"Takagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2016.04.023_bib1","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1474-4422(10)70198-8","article-title":"Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial","volume":"9","author":"Shinohara","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jphs.2016.04.023_bib2","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.12.002","article-title":"Efficacy and safety of cilostazol therapy in ischemic stroke: a meta-analysis","volume":"24","author":"Tan","year":"2015","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jphs.2016.04.023_bib3","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/STR.0000000000000069","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"46","author":"Hemphill","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.jphs.2016.04.023_bib4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s12028-009-9271-3","article-title":"Is platelet activity important in acute intracerebral hemorrhage?","volume":"11","author":"Wijman","year":"2009","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.jphs.2016.04.023_bib5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2008.01.003","article-title":"The blood-brain barrier in health and chronic neurodegenerative disorders","volume":"57","author":"Zlokovic","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.jphs.2016.04.023_bib6","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/nm.3407","article-title":"Development, maintenance and disruption of the blood-brain barrier","volume":"19","author":"Obermeier","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jphs.2016.04.023_bib7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.neulet.2009.01.039","article-title":"Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage","volume":"452","author":"Nonaka","year":"2009","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jphs.2016.04.023_bib8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.mvr.2004.05.002","article-title":"Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production","volume":"68","author":"Omi","year":"2004","journal-title":"Microvasc Res"},{"key":"10.1016\/j.jphs.2016.04.023_bib9","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/ATVBAHA.108.164368","article-title":"Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells","volume":"28","author":"Ota","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jphs.2016.04.023_bib10","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1161\/STROKEAHA.110.609834","article-title":"Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats","volume":"42","author":"Oyama","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.jphs.2016.04.023_bib11","doi-asserted-by":"crossref","first-page":"e44476","DOI":"10.1371\/journal.pone.0044476","article-title":"Cilostazol prevents endothelin-induced smooth muscle constriction and proliferation","volume":"7","author":"Kawanabe","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jphs.2016.04.023_bib12","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.5551\/jat.4309","article-title":"Inhibitory effects of cilostazol on proliferation of vascular smooth muscle cells (VSMCs) through suppression of the ERK1\/2 pathway","volume":"17","author":"Yoo","year":"2010","journal-title":"J\u00a0Atheroscler Thromb"},{"key":"10.1016\/j.jphs.2016.04.023_bib13","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1179\/1743132814Y.0000000389","article-title":"The effect of cilostazol and aspirin pre-treatment against subsequent transient focal cerebral ischemia in rat","volume":"36","author":"Toda","year":"2014","journal-title":"Neurol Res"},{"key":"10.1016\/j.jphs.2016.04.023_bib14","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1161\/STROKEAHA.111.643098","article-title":"Clinical and pathological improvement in stroke-prone spontaneous hypertensive rats related to the pleiotropic effect of cilostazol","volume":"43","author":"Omote","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.jphs.2016.04.023_bib15","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.11.023","article-title":"The effect of acute medication with cilostazol, an anti-platelet drug, on the outcome of small vessel brain infarction","volume":"23","author":"Nakase","year":"2014","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jphs.2016.04.023_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000369610","article-title":"Final results of cilostazol-aspirin therapy against recurrent stroke with intracranial artery stenosis (CATHARSIS)","volume":"5","author":"Uchiyama","year":"2015","journal-title":"Cerebrovasc Dis Extra"},{"key":"10.1016\/j.jphs.2016.04.023_bib17","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1161\/CIRCULATIONAHA.112.000711","article-title":"Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the sufficient treatment of peripheral intervention by cilostazol study","volume":"127","author":"Iida","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jphs.2016.04.023_bib18","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/jcph.64","article-title":"Addition of cilostazol to conventional dual antiplatelet therapy reduces the risk of cardiac events and restenosis after drug-eluting stent implantation: a meta-analysis","volume":"53","author":"Chen","year":"2013","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jphs.2016.04.023_bib19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/jcbfm.2008.164","article-title":"Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain","volume":"29","author":"Yamashita","year":"2009","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"key":"10.1016\/j.jphs.2016.04.023_bib20","doi-asserted-by":"crossref","first-page":"e15178","DOI":"10.1371\/journal.pone.0015178","article-title":"Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA","volume":"5","author":"Ishiguro","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jphs.2016.04.023_bib21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/STROKEAHA.111.635417","article-title":"Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model","volume":"43","author":"Kasahara","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.jphs.2016.04.023_bib22","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/sj.jcbfm.9600375","article-title":"Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat","volume":"27","author":"Yang","year":"2007","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"key":"10.1016\/j.jphs.2016.04.023_bib23","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1161\/01.STR.0000177517.01203.eb","article-title":"Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia","volume":"36","author":"Tsuji","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.jphs.2016.04.023_bib24","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1161\/STROKEAHA.113.001183","article-title":"Cilostazol ameliorates warfarin-induced hemorrhagic transformation after cerebral ischemia in mice","volume":"44","author":"Kitashoji","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.jphs.2016.04.023_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/0271678X15621499","article-title":"Cilostazol ameliorates collagenase-induced cerebral hemorrhage by protecting the blood-brain barrier","author":"Takagi","year":"2015","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"key":"10.1016\/j.jphs.2016.04.023_bib26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.phrs.2006.10.010","article-title":"Cilostazol inhibits the redistribution of the actin cytoskeleton and junctional proteins on the blood-brain barrier under hypoxia\/reoxygenation","volume":"55","author":"Torii","year":"2007","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jphs.2016.04.023_bib27","doi-asserted-by":"crossref","first-page":"e89516","DOI":"10.1371\/journal.pone.0089516","article-title":"Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study","volume":"9","author":"Ihara","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jphs.2016.04.023_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pbb.2015.05.006","article-title":"Efficacy of Cilostazol a selective phosphodiesterase-3 inhibitor in rat model of Streptozotocin diabetes induced vascular dementia","volume":"135","author":"Kumar","year":"2015","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.jphs.2016.04.023_bib29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nbd.2014.08.034","article-title":"Diabetes augments cognitive dysfunction in chronic cerebral hypoperfusion by increasing neuronal cell death: implication of cilostazol for diabetes mellitus-induced dementia","volume":"73","author":"Kwon","year":"2015","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.jphs.2016.04.023_bib30","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/acn3.79","article-title":"Phosphodiesterase III inhibitor promotes drainage of cerebrovascular beta-amyloid","volume":"1","author":"Maki","year":"2014","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861316300512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861316300512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T14:21:04Z","timestamp":1536762064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861316300512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1347861316300512"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2016.04.023","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protective effects of cilostazol against hemorrhagic stroke: Current and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2016.04.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}